human
immunodefici
viru
type
transmembran
glycoprotein
target
broadlyreact
neutral
antibodi
make
attract
target
vaccin
develop
better
assess
immunogen
properti
gener
five
solubl
glutathion
stransferas
fusion
protein
encompass
ctermin
fulllength
amino
acid
ectodomain
group
consensu
envelop
sequenc
antibodi
respons
patient
evalu
use
protein
overlap
peptid
found
antibodi
respons
differ
region
vari
tremend
among
individu
patient
ii
patient
stronger
antibodi
respons
membraneproxim
extern
region
exhibit
broader
potent
neutral
activ
iii
sever
patient
mount
antibodi
epitop
near
overlap
target
solubl
fusion
protein
could
import
sourc
antigen
futur
vaccin
develop
effort
human
immunodefici
viru
type
infect
mani
antibodi
elicit
viral
envelop
glycoprotein
vast
major
antibodi
nonneutr
neutral
mostli
isolatespecif
review
see
poignard
et
al
result
activ
passiv
immun
studi
indic
preexist
neutral
antibodi
nab
confer
protect
infect
baba
et
al
cho
et
al
conley
et
al
mascola
et
al
parren
et
al
shibata
et
al
trkola
et
al
howev
precis
role
humor
immun
control
natur
infect
yet
clear
better
understand
antibodi
respons
envelop
glycoprotein
virusinfect
patient
may
facilit
develop
protect
vaccin
viru
antisera
exhibit
broadli
neutral
activ
divers
isol
observ
longterm
nonprogressor
ltnp
braibant
et
al
cecilia
et
al
pilgrim
et
al
howev
rare
despit
two
decad
aid
research
hand
broadli
reactiv
nab
brnab
identifi
includ
monoclon
antibodi
mab
gorni
et
al
muster
et
al
roben
et
al
stiegler
et
al
trkola
et
al
zhang
et
al
zwick
et
al
first
three
antibodi
latter
three
target
antibodi
target
great
interest
vaccin
develop
standpoint
crossreact
virus
differ
clade
direct
binley
et
al
burton
et
al
opalka
et
al
yust
et
al
zwick
et
al
monoclon
antibodi
target
adjac
distinct
linear
epitop
highli
conserv
region
near
viral
membran
known
membraneproxim
extern
region
mper
muster
et
al
stiegler
et
al
zhang
et
al
zwick
et
al
determin
play
critic
role
fusion
cell
membran
salzwedel
west
hunter
suarez
et
al
epitop
map
studi
synthet
peptid
barbato
et
al
biron
et
al
joyc
et
al
phage
display
peptid
librari
menendez
et
al
muster
et
al
zwick
et
al
proteas
protect
assay
parker
et
al
identifi
eldkwa
core
antibodi
bind
site
bind
primarili
hexapeptid
nwfnit
lie
four
amino
acid
downstream
epitop
brunel
et
al
cardoso
et
al
stiegler
et
al
zwick
et
al
epitop
yet
precis
defin
although
thought
distinct
recogn
highli
conform
requir
proper
disulfid
bond
format
zhang
et
al
past
two
decad
much
vaccin
develop
effort
focus
consequ
much
less
known
immunolog
properti
effort
evalu
immunogen
hamper
fact
protein
either
whole
part
difficult
express
solubl
form
absenc
gairin
et
al
luo
et
al
qiao
et
al
scholz
et
al
weissenhorn
et
al
moreov
larg
number
highli
immunogen
epitop
render
unsuit
assess
immunogen
properti
particularli
mper
pantophlet
burton
wei
et
al
addit
assess
antibodi
respons
virusinfect
patient
done
mostli
context
short
synthet
peptid
calarota
et
al
gnann
nelson
oldston
goudsmit
meloen
brasseur
horal
et
al
schrier
et
al
peptid
suitabl
identifi
linear
epitop
antibodi
respons
noncontigu
conform
epitop
assess
date
effort
express
solubl
form
limit
small
fragment
protein
includ
heptad
repeat
hr
region
root
kay
kim
immunodomin
loop
known
cluster
gnann
nelson
oldston
region
epitop
known
cluster
ii
binley
et
al
goudsmit
meloen
brasseur
xu
et
al
mper
luo
et
al
opalka
et
al
although
scholz
et
al
scholz
et
al
report
gener
larger
amino
acid
fragment
residu
fuse
e
coli
chaperon
slyd
show
immunoreact
patient
sera
immunoprob
perform
use
mab
confirm
antigen
integr
protein
studi
systemat
gener
five
glutathion
stransferas
gst
fusion
protein
consist
ctermin
fulllength
amino
acid
residu
ectodomain
group
consensu
envelop
sequenc
express
e
coli
solubil
purifi
protein
conjunct
consensu
overlap
peptid
use
evalu
antibodi
respons
patient
assess
antibodi
respons
conform
noncontigu
epitop
patient
construct
five
fragment
fuse
gluthionestransferas
gst
gst
chosen
fusion
partner
facilit
protein
refold
process
protein
truncat
ntermin
amino
acid
apart
contain
ctermin
entir
aa
protein
fig
therefor
design
encompass
mper
contain
epitop
recogn
mab
truncat
site
chosen
either
upor
downstream
hr
domain
addit
site
chosen
ntermin
end
fragment
would
charg
amino
acid
ie
rq
er
de
ek
protein
tag
sixhistidin
residu
cterminu
facilit
protein
renatur
purif
order
enhanc
protein
recognit
antisera
patient
infect
wide
rang
primari
isol
differ
clade
chose
gener
fragment
envelop
group
consensu
sequenc
five
fusion
protein
express
effici
e
coli
upon
induct
iptg
fig
expect
five
protein
insolubl
anticip
difficulti
solubil
two
larger
fragment
initi
effort
focus
bacteri
pellet
sonic
inclus
bodi
isol
denatur
urea
solubil
protein
bound
ninta
resin
subsequ
protein
renatur
gradual
sequenti
incub
decreas
concentr
urea
final
wash
pb
elut
resin
use
imidazol
elut
protein
final
dialyz
pb
singlestep
purif
renatur
procedur
yield
mg
per
liter
respect
puriti
fig
ident
purifi
protein
confirm
western
immunoblot
use
antigst
antibodi
fig
minor
band
unknown
ident
kd
copurifi
fig
contamin
like
cleavag
product
gst
sinc
immunoreact
antigstantibodi
fig
verifi
fusion
protein
antigen
correct
subject
immunoprecipit
analys
use
brnab
follow
western
immunoblot
antigst
antibodi
shown
fig
three
protein
recogn
respect
recognit
howev
appear
somewhat
weaker
seen
bind
observ
gst
protein
demonstr
specif
recognit
mper
success
gener
solubl
pursu
gener
solubl
solubil
two
larger
protein
difficult
initi
follow
protocol
use
solubil
smaller
protein
howev
result
precipit
protein
even
urea
hypothes
slower
transit
provid
time
need
protein
refold
conform
would
render
protein
solubl
use
continu
shallow
gradient
see
materi
method
section
detail
abl
maintain
signific
portion
protein
solubl
fig
typic
final
yield
mgliter
respect
significantli
lower
smaller
fusion
protein
suffici
studi
addit
difficulti
solubil
protein
observ
protein
would
precipit
upon
repeat
freezingandthaw
prevent
protein
precipit
work
stock
protein
kept
near
ice
bath
cold
room
elisa
perform
evalu
antigen
properti
purifi
fusion
protein
quantit
protein
probe
brnab
polyclon
hivig
pool
patient
sera
mab
recogn
coiledcoil
structur
region
bundl
gorni
et
al
taniguchi
et
al
well
coat
equimolar
amount
protein
assess
rel
antigen
similarli
reactiv
five
protein
fragment
indic
epitop
recogn
antibodi
conform
similar
equal
expos
among
five
protein
fig
contrast
variat
recognit
protein
observ
despit
fact
protein
contain
epitop
recogn
antibodi
fig
compar
equal
reactiv
less
reactiv
respect
somewhat
surpris
consid
bind
site
amino
acid
downstream
epitop
addit
bind
strength
significantli
weaker
five
protein
compar
requir
approxim
fold
higher
concentr
fig
unexpect
sinc
exhibit
rel
weak
albeit
broad
neutral
activ
binley
et
al
react
strongli
indic
protein
exist
posthairpin
format
configur
fig
predict
three
smaller
protein
detect
sinc
contain
heptad
repeat
region
requir
form
coiledcoil
structur
similar
hivig
react
strongli
fig
although
fusion
protein
significantli
less
reactiv
hivig
compar
antibodi
could
detect
use
higher
concentr
antibodi
longer
enzymat
reaction
time
fig
among
three
smaller
protein
hivig
react
strongli
expect
sinc
contain
immunodomin
domain
fig
also
reactiv
albeit
less
contrast
react
weakli
support
notion
mper
poorli
immunogen
context
natur
infect
evalu
antibodi
respons
envelop
glycoprotein
use
hivig
provid
overal
pictur
antibodi
prepar
larg
number
virusinfect
patient
sera
hypothes
might
see
differ
amongst
individu
patient
consid
signific
polymorph
host
immun
system
andor
variat
viral
genom
result
studi
describ
demonstr
solubl
gstfusion
protein
gener
antigen
intact
suitabl
assess
immun
respons
patient
sinc
epitop
target
brnab
identifi
date
map
within
ctermin
amino
acid
focus
effort
character
antibodi
respons
archiv
plasma
sampl
patient
evalu
elisa
use
equimolar
amount
three
gst
fusion
protein
purifi
gst
protein
use
neg
control
result
shown
fig
patient
sampl
arrang
descend
order
magnitud
antibodi
reactiv
number
though
fortyfour
patient
two
antiretrovir
therapi
time
plasma
sampl
taken
overal
strongest
antibodi
respons
detect
use
follow
consist
observ
use
hivig
fig
mean
valu
fig
median
valu
fig
respect
interestingli
observ
tremend
variat
amongst
individu
patient
antibodi
reactiv
three
fragment
term
magnitud
bind
pattern
hypothes
patient
exhibit
low
antibodi
titer
three
fragment
eg
wherea
other
mount
strong
antibodi
respons
eg
patient
show
good
bind
eg
patient
exhibit
good
reactiv
eg
gener
antibodi
respons
variabl
standard
deviat
compar
respect
fig
interestingli
markedli
greater
antibodi
respons
observ
seven
patient
despit
fact
latter
protein
larger
one
possibl
explan
immunogen
epitop
recogn
particular
patient
buri
context
perhap
intrigu
aspect
studi
mani
patient
mount
strong
antibodi
respons
mper
three
particular
demonstr
antibodi
reactiv
retrospect
analys
patient
show
mani
patient
might
consid
slow
progressor
infect
longer
year
tcell
count
never
antiretrovir
therapi
indic
black
bar
top
fig
gener
exhibit
higher
antibodi
reactiv
previou
studi
shown
brnab
stronger
frequent
ltnp
infect
patient
cecilia
et
al
pilgrim
et
al
result
rais
possibl
patient
could
brnab
target
mper
could
exhibit
properti
test
hypothesi
patient
mount
stronger
antibodi
respons
might
broader
neutral
activ
compar
neutral
activ
antisera
six
patient
highest
reactiv
six
patient
lower
reactiv
indic
dot
asterisk
fig
respect
latter
sampl
chosen
semirandomli
make
sure
good
antibodi
reactiv
neutral
assay
perform
four
primari
isol
bal
use
singleround
pseudoviru
infect
assay
virus
pseudotyp
vesicular
stomat
viru
g
protein
vsvg
use
neg
control
although
absolut
correl
antibodi
reactiv
breadth
potenc
neutral
activ
individu
patient
basi
overal
plasma
patient
higher
reactiv
exhibit
broader
potent
activ
fig
p
particularli
true
patient
also
noteworthi
plasma
sampl
patient
effici
neutral
one
difficult
virus
elicit
neutral
antibodi
bower
et
al
cho
et
al
kim
et
al
kim
et
al
none
six
sampl
lower
reactiv
exhibit
strong
neutral
activ
viru
contrast
plasma
sampl
twelv
patient
neutral
quit
effect
suggest
viru
might
particularli
sensit
neutral
despit
primari
isol
titrat
analys
plasma
sampl
six
patient
strong
reactiv
confirm
potent
neutral
activ
patient
fig
analys
show
patient
also
exhibit
quit
potent
neutral
activ
virus
albeit
somewhat
less
effect
none
plasma
sampl
neutral
virus
pseudotyp
vsvg
data
shown
indic
specif
antibodymedi
neutral
base
neutral
assay
four
isol
exhibit
broadest
potent
neutral
activ
determin
extent
breadth
neutral
assay
perform
viru
isol
includ
sixteen
clade
b
four
clade
c
four
clade
shown
tabl
plasma
sampl
patient
abl
neutral
virus
test
albeit
differ
potenc
isol
mn
histor
easili
neutraliz
tier
virus
wherea
virus
standard
refer
panel
subtyp
b
env
clone
nih
arrrp
cat
subtyp
c
design
tier
studi
consid
neither
unusu
sensit
resist
neutral
base
past
experi
montefiori
patient
sampl
level
breadth
potenc
neutral
activ
present
epitop
target
neutral
antibodi
known
despit
lack
absolut
correl
antibodi
reactiv
breadth
potenc
neutral
activ
individu
patient
basi
fact
four
six
patient
highest
reactiv
protein
exhibit
strong
neutral
activ
suggest
someth
might
uniqu
patient
character
antibodi
respons
patient
immunogen
linear
epitop
examin
elisa
use
overlap
peptid
aa
overlap
span
amino
acid
residu
number
base
peptid
three
recogn
strongli
six
patient
fig
two
peptid
lgiwgcsgklicttt
gcsgklictttvpwn
within
immunodomin
domain
cluster
design
aa
rvlaverylkdqqllgiwgcsgkl
binley
et
al
sinc
peptid
exhibit
similar
antibodi
reactiv
profil
core
epitop
like
consist
residu
gcsgklicttt
contain
cystein
residu
previous
report
critic
recognit
gnann
nelson
oldston
four
peptid
upstream
one
peptid
downstream
two
immunodomin
peptid
cluster
also
reactiv
certain
patient
plasma
interest
note
peptid
recogn
patient
plasma
exhibit
broader
potent
neutral
activ
patient
mount
detect
antibodi
epitop
within
peptid
shown
antibodi
target
immunodomin
epitop
neutral
remain
determin
whether
antibodi
bind
epitop
adjac
immunodomin
epitop
neutral
activ
third
highli
immunoreact
peptid
qekneqellaldkwa
found
region
overlap
cluster
ii
design
aa
rlieesqnqqekneqel
binley
et
al
peptid
contain
residu
aldkwa
core
epitop
mab
eldkwa
muster
et
al
consid
part
cluster
ii
binley
et
al
goudsmit
meloen
brasseur
fact
peptid
upstream
sqnqqekneqel
recogn
none
patient
plasma
indic
critic
particip
andor
contribut
residu
dkwa
form
correct
conform
epitop
within
peptid
interest
two
reason
firstli
patient
ie
except
also
recogn
peptid
downstream
eqellaldkwaslwn
secondli
direct
elisa
analys
show
antibodi
bind
peptid
fig
therefor
believ
patient
may
mount
antibodi
similar
epitop
recognit
neutral
activ
natur
infect
one
strike
find
studi
antibodi
patient
bound
strongli
peptid
lwnwfditnwlwyik
nwlwyikifimivgg
fig
two
peptid
recogn
mab
fig
although
bind
primarili
residu
nwfdit
antibodi
known
also
interact
sequenc
downstream
eg
brunel
et
al
strongli
suggest
although
prove
may
mount
antibodi
moreov
antibodi
patient
bound
strongli
peptid
laldkwaslwnwfdi
contain
epitop
recogn
almost
complet
entireti
regard
antibodi
recogn
peptid
might
properti
fab
fragment
shown
bind
epitop
overlap
residu
epitop
nelson
et
al
zwick
et
al
anoth
interest
observ
antibodi
patient
exhibit
potent
broad
neutral
activ
strongli
react
peptid
eiwdnmtwmewerei
peptid
encompass
motif
highli
homolog
domain
wnnmtwmew
scaffold
protein
organ
concentr
specif
ligand
within
caveola
membran
bind
site
recent
shown
play
import
role
format
fusion
pore
endocytosi
huang
et
al
draw
interest
find
rabbit
immun
peptid
encompass
bind
domain
sleqiwnnmtwmqwdk
mount
quit
broad
neutral
activ
multipl
primari
isol
differ
clade
hovanessian
et
al
therefor
one
possibl
sourc
broadli
neutral
activ
patient
antibodi
direct
bind
domain
shown
fig
antibodi
reactiv
significantli
greater
patient
case
even
six
patient
highest
reactiv
except
show
similar
reactiv
howev
elisa
analys
use
aa
peptid
reveal
almost
antibodi
reactiv
ctermin
residu
upstream
mper
ie
aa
fig
antibodi
reactiv
observ
even
much
longer
aa
peptid
use
encompass
entir
domain
fig
second
panel
result
indic
antibodi
specif
recogn
like
bind
highli
conform
andor
noncontigu
epitop
form
presenc
ctermin
residu
ie
mper
interpret
consist
previou
studi
report
antibodi
direct
cluster
iii
aa
highli
conform
binley
et
al
although
none
patient
highand
lowreact
analyz
mount
detect
antibodi
respons
either
peptid
correspond
region
respect
fig
first
second
panel
show
equal
strong
reactiv
bundl
protein
complex
fig
third
panel
monomer
polypeptid
consist
three
two
segment
connect
linker
sequenc
design
mimic
trimer
coiledcoil
structur
root
kay
kim
strong
respons
like
result
antibodi
nonfunct
trimer
stump
surfac
virion
expos
shed
moor
et
al
expect
mab
recogn
bundl
peptid
fig
fourth
panel
elisa
result
fig
reveal
plasma
sampl
patient
exhibit
peptid
reactiv
profil
resembl
antibodi
ie
recognit
peptid
peptid
consid
patient
might
inde
antibodi
curiou
preval
patient
antisera
exhibit
similar
profil
conduct
elisa
analys
patient
sampl
simultan
except
due
insuffici
amount
use
eight
peptid
span
entir
mper
two
peptid
cluster
immunodomin
domain
also
evalu
unrel
peptid
sarscov
spike
glycoprotein
aa
use
neg
control
although
two
immunodomin
peptid
highli
reactiv
individu
onefourth
patient
mount
surprisingli
weak
antibodi
respons
region
valu
less
fig
gener
antibodi
reactiv
peptid
correl
howev
sever
notabl
except
antibodi
reactiv
weak
eg
patient
plasma
sampl
eight
patient
indic
triangl
react
substanti
background
level
peptid
suggest
patient
might
mount
antibodi
one
patient
fairli
strong
antibodi
reactiv
plasma
sever
patient
react
substanti
peptid
eg
patient
suggest
might
antibodi
nelson
et
al
zwick
et
al
final
plasma
four
patient
react
peptid
recogn
weak
near
background
level
antibodi
reactiv
observ
peptid
togeth
result
suggest
sever
patient
develop
antibodi
epitop
near
overlap
target
view
limit
number
brnab
identifi
date
better
character
antibodi
respons
patient
identif
new
potent
brnab
critic
design
vaccin
immunogen
first
step
effort
toward
achiev
goal
systemat
gener
purifi
five
solubl
fusion
protein
contain
ctermin
amino
acid
ectodomain
group
consensu
sequenc
recombin
protein
appear
intact
antigen
structur
base
immunoprob
analys
brnab
antisera
patient
character
antibodi
respons
larg
limit
short
peptid
protein
difficult
produc
solubl
form
therefor
set
fragment
gener
invalu
reagent
character
antibodi
respons
express
eukaryot
viral
protein
bacteria
typic
result
misfold
aggreg
protein
accumul
inclus
bodi
protein
fragment
except
despit
fact
fuse
gst
howev
success
denatur
protein
refold
renatur
solubl
form
absenc
deterg
although
experienc
greater
difficulti
solubil
two
larger
fragment
obtain
substanti
lower
yield
although
attempt
express
protein
fragment
without
gst
quit
certain
gst
play
critic
role
allow
protein
renatur
solubl
form
conclus
base
part
observ
attempt
remov
gst
cleav
two
fusion
partner
thrombin
result
immedi
precipit
data
shown
specul
gst
could
function
way
analog
mask
hydrophob
patch
away
aqueou
solvent
prevent
nonspecif
aggreg
sinc
fusion
protein
antigen
intact
shown
abil
bind
brnab
also
conform
antibodi
bind
cluster
iii
could
potenti
candid
vaccin
develop
howev
protein
ideal
antigen
vaccin
larg
gst
portion
like
immunodomin
smaller
fragment
hand
protein
highli
suitabl
structur
studi
especi
sinc
well
recogn
easili
produc
mg
protein
one
liter
bacteri
cultur
date
solv
crystal
structur
coiledcoil
core
peptid
epitop
bind
cardoso
et
al
chan
et
al
ofek
et
al
tan
et
al
weissenhorn
et
al
determin
structur
entir
mper
domain
would
facilit
better
understand
function
design
antigen
elicit
antibodi
five
fusion
protein
equal
well
recogn
indic
epitop
conform
ident
similarli
expos
amongst
protein
fig
although
five
protein
also
recogn
less
reactiv
respect
compar
three
protein
fig
result
somewhat
unexpect
take
account
epitop
consid
linear
four
amino
acid
downstream
epitop
one
like
explan
although
epitop
linear
highli
conform
requir
region
proper
format
antigen
epitop
structur
regard
previous
report
epitop
assum
helic
conform
cardoso
et
al
modif
enhanc
helic
properti
increas
antibodybind
affin
brunel
et
al
cardoso
et
al
base
find
current
hypothes
sequenc
within
upstream
mper
ie
ctermin
residu
provid
constraint
helic
conform
epitop
therebi
enhanc
antibodi
bind
compar
addit
sequenc
within
either
disrupt
mask
epitop
partial
reduc
bind
inhibit
revers
domain
form
coiledcoil
structur
demonstr
reactiv
mab
fig
detail
biochem
structur
analys
need
test
hypothes
observ
tremend
variat
antibodi
respons
amongst
differ
patient
respect
magnitud
also
pattern
antibodi
reactiv
differ
fragment
peptid
one
paramet
could
affect
magnitud
antibodi
respons
plasma
viral
load
greater
antigen
stimul
might
expect
induc
stronger
antibodi
respons
regard
durat
infect
sinc
seroconvers
possibl
treatment
patient
antiretrovir
therapi
could
potenti
influenc
antibodi
level
binley
et
al
lafeuillad
et
al
morri
et
al
import
contribut
may
also
stem
overal
respons
patient
immun
system
antigen
stimul
higher
viral
load
could
also
mean
greater
deterior
helper
cell
immun
therefor
weaker
b
cell
respons
present
studi
patient
chosen
randomli
without
consider
paramet
primarili
interest
studi
differenti
epitop
target
individu
patient
identifi
mount
strong
antibodi
respons
potenti
neutral
epitop
viz
mper
variat
antibodi
respons
differ
region
peptid
differ
patient
could
attribut
differ
patient
immun
system
eg
immunoglobulin
gene
repertoir
andor
isol
patient
infect
eg
envelop
protein
sequenc
saw
mani
patient
mount
strong
antibodi
respons
mper
ie
reactiv
exhibit
broader
potent
neutral
activ
compar
emphas
howev
present
know
epitop
target
nab
could
direct
mper
region
epitop
within
furthermor
breadth
neutral
activ
could
polyclon
multipl
nab
target
differ
epitop
event
character
b
cell
repertoir
viru
isol
patient
mab
gener
patient
could
provid
clue
brnab
could
elicit
consid
plasma
sampl
four
six
patient
show
strong
antibodi
reactiv
potent
neutral
activ
fusion
protein
could
use
tool
rapidli
screen
patient
sera
identifi
might
brnab
regard
somewhat
disappoint
fact
patient
whose
antisera
react
strongli
protein
exhibit
potent
neutral
activ
hope
one
possibl
explan
might
epitop
mper
elicit
nonneutr
antibodi
conceiv
antibodi
could
prevent
bind
nab
target
epitop
close
proxim
due
steric
hindranc
eg
case
observ
neutral
activ
would
determin
rel
antibodi
titer
affin
neutral
nonneutr
antibodi
compet
adjac
epitop
hypothesi
true
would
strong
implic
term
vaccin
design
antigen
correct
neutral
epitop
antigen
compet
nonneutr
epitop
nearbi
attempt
elicit
antibodi
similar
properti
anim
immun
antigen
contain
mper
success
propos
difficulti
due
autoantigen
mimicri
base
observ
crossreact
phospholipid
cardiolipin
alam
et
al
hayn
et
al
sanchezmartinez
et
al
view
properti
autoantibodi
quit
controversi
sinc
use
passiv
immun
studi
without
complic
ferrantelli
et
al
joo
et
al
trkola
et
al
addit
recent
publish
studi
report
fail
exhibit
cardiolipin
reactiv
set
experiment
condit
scherer
et
al
also
gener
affin
lipid
reactiv
resembl
antiphospholipid
antibodi
elicit
mani
infect
rather
autoimmun
antiphospholipid
syndrom
thu
inabl
elicit
antibodi
similar
properti
might
attribut
immun
toler
mechan
studi
identifi
mani
patient
mount
antibodi
peptid
recogn
lesser
extent
fig
although
yet
determin
precis
epitop
specif
antibodi
result
studi
suggest
patient
mount
antibodi
epitop
near
overlap
target
may
rare
previous
thought
agreement
find
gray
et
al
gray
et
al
recent
report
onethird
patient
mount
nab
mper
addit
studi
larger
panel
patient
sampl
detail
biochem
analys
purifi
antibodi
target
mper
could
provid
definit
answer
regard
fusion
protein
gener
could
ideal
reagent
rapid
assess
antibodi
respons
affin
purif
mperdirect
antibodi
gener
plasmid
construct
express
five
fusion
protein
region
encod
ctermin
amino
acid
group
consensu
ectodomain
pcramplifi
kindli
provid
dr
beatric
hahn
univers
alabama
pcr
reaction
carri
use
common
revers
primer
five
construct
individu
forward
primer
underlin
doubl
underlin
sequenc
indic
restrict
enzym
site
bamhi
ecori
respect
amplifi
dna
fragment
digest
bamhi
ecori
ligat
correspond
site
vector
ge
healthcar
life
scienc
contain
inadvert
inconsequenti
mutat
number
base
ecoli
transform
recombin
plasmid
cultur
overnight
superbroth
contain
ampicillin
cell
dilut
fresh
superbroth
cultur
od
time
fusion
protein
express
induc
iptg
isopropylbetadthiogalactopyranosid
h
cell
harvest
wash
lyse
pb
phosphatebuff
salin
sonic
cell
lysat
subject
centrifug
rpm
rotor
min
sorval
superspe
centrifug
pellet
contain
inclus
bodi
wash
pb
solubil
pb
contain
urea
insolubl
debri
remov
centrifug
solubl
protein
bound
ninta
resin
qiagen
column
renatur
serial
incub
bed
volum
pb
contain
decreas
step
gradient
urea
renatur
fusion
protein
requir
much
slower
continu
gradient
reduct
urea
concentr
particularli
process
typic
took
place
period
day
column
wash
pb
contain
mm
imidazol
protein
elut
pb
contain
mm
imidazol
elut
protein
dialyz
pb
concentr
determin
bradford
assay
puriti
assess
sdspage
follow
silver
stain
nonfus
gst
express
similarli
purifi
protein
cell
lyse
pb
sonic
lysat
subject
centrifug
rpm
rotor
min
gst
purifi
accord
manufactur
protocol
novagen
briefli
resin
ad
supernat
incub
min
gstbound
resin
pellet
centrifug
wash
twice
pb
load
onto
column
wash
gst
bindingwash
buffer
mm
na
hpo
mm
kh
po
nacl
mm
kcl
ph
gst
elut
buffer
mm
trishcl
ph
contain
mm
reduc
glutathion
elut
protein
dialyz
pb
concentr
determin
bradford
assay
mab
buchach
et
al
purtscher
et
al
purtscher
et
al
obtain
dr
hermann
kating
nih
aid
research
refer
reagent
program
nih
arrrp
immunoprecipit
ip
done
incub
gst
fusion
protein
either
protein
agaros
ip
buffer
mm
tri
ph
mm
nacl
mm
edta
triton
mixtur
agit
overnight
subsequ
antigenantibodi
complex
bound
protein
agaros
wash
three
time
ip
buffer
protein
denatur
elut
resin
heat
boil
water
min
sdspage
sampl
buffer
immunoprecipit
purifi
protein
subject
sdspage
acrylamid
follow
western
blot
analys
use
rabbit
antigst
igg
molecular
probe
goat
antirabbit
igg
conjug
horseradish
peroxidas
pierc
protein
band
visual
supersign
chemiluminesc
substrat
pierc
accord
manufactur
protocol
plasma
sampl
patient
obtain
case
western
reserv
univers
center
aid
research
clinic
core
sampl
heat
inactiv
min
prior
use
bundl
protein
root
kay
kim
kindli
provid
dr
michael
root
thoma
jefferson
univers
follow
reagent
obtain
nih
arrrp
hivig
nabi
nhlbl
group
consensu
envelop
overlap
peptid
cat
iiib
peptid
gallo
et
al
cat
respect
daid
mab
gorni
et
al
robinson
et
al
tyler
et
al
xu
et
al
dr
susan
zollapazn
sarscov
protein
peptid
pfysnvtgfhtinhtf
cat
obtain
nih
biodefens
emerg
infect
research
resourc
repositori
purifi
fusion
protein
overlap
peptid
pmole
per
well
respect
coat
onto
nuncimmuno
plate
nunc
cat
use
antigen
coat
buffer
mm
na
co
mm
nahco
mm
nan
ph
overnight
antigen
coat
ngwell
well
block
pb
ph
contain
skim
milk
fb
h
wash
four
time
tween
pb
ad
patient
plasma
sampl
final
dilut
block
buffer
antibodi
plasma
sampl
dilut
indic
ad
well
incub
h
block
buffer
well
wash
time
secondari
antibodi
goat
antihuman
igg
conjug
horseradish
peroxidas
pierc
cat
incub
dilut
well
wash
time
develop
ad
tmb
hrpsubstrat
biorad
min
reaction
stop
n
h
plate
read
micropl
reader
versamax
molecular
devic
experi
done
duplic
singl
round
infect
assay
tzmbl
cell
derdeyn
et
al
platt
et
al
wei
et
al
use
pseudovirus
perform
other
previous
describ
derdeyn
et
al
kim
et
al
wei
et
al
wei
et
al
assay
done
two
laboratori
slightli
differ
protocol
cho
lab
pseudovirus
gener
use
connor
et
al
et
al
pcmvtat
jeang
et
al
construct
encod
isol
bal
phcmvg
encod
vsvg
protein
burn
et
al
briefli
cell
confluenc
flask
cotransfect
calcium
phosphat
method
phcmvg
construct
pcmvtat
transfect
cell
incub
h
replac
medium
cell
cultur
two
day
time
cultur
medium
collect
clarifi
centrifug
cellfre
viru
stock
aliquot
store
pseudovirus
titer
tzmbl
cell
stain
previous
describ
wei
et
al
cell
cultur
co
dmem
supplement
fb
penicillinstreptomycin
glutamin
heatinactiv
plasma
sampl
mab
dilut
serumfre
dmem
indic
concentr
mix
infecti
unit
pseudovirus
mixtur
incub
ad
tzmbl
target
cell
plate
h
adsorpt
viru
inoculum
remov
fresh
medium
ad
two
dayspost
infect
cell
lyse
viru
infect
determin
use
luminesc
assay
per
manufactur
protocol
promega
rel
luminesc
unit
rlu
measur
use
luminomet
biorad
assay
perform
duplic
quadrupl
uninfect
tzmbl
cell
use
determin
background
luminesc
mean
background
subtract
read
viru
infect
determin
percentag
noserum
control
ie
viru
montefiori
lab
assay
also
done
tzmbl
cell
describ
briefli
tcid
viru
incub
serial
dilut
serum
sampl
triplic
total
volum
hr
flatbottom
cultur
plate
freshli
trypsin
cell
cell
growth
medium
contain
deae
dextran
ad
well
one
set
control
well
receiv
cell
viru
viru
control
anoth
set
receiv
cell
background
control
incub
cell
transfer
black
solid
plate
costar
measur
luminesc
use
britelit
luminesc
report
gene
assay
system
perkinelm
life
scienc
assay
stock
envpseudotyp
virus
prepar
transfect
cell
titrat
tzmbl
cell
describ
purpos
compar
high
low
patient
group
breadth
neutral
activ
summari
infect
individu
patient
calcul
averag
infect
observ
individu
across
four
virus
statist
independ
summari
valu
infect
use
compar
group
use
two
group
ttest
nonparametr
wilcoxon
rank
sum
test
observ
neutral
four
virus
significantli
higher
p
high
antibodi
bind
group
test
purifi
gst
fusion
protein
analyz
elisa
use
mab
b
c
polyclon
hivig
e
equimolar
amount
pmole
gst
fusion
protein
coat
well
detect
three
smaller
fusion
protein
hivig
higher
concentr
antibodi
use
extend
enzymat
reaction
time
panel
e
env
pseudotyp
virus
bal
use
assess
neutral
activ
tzmbl
cellbas
assay
data
shown
percentag
viru
infect
absenc
plasma
twelv
patient
identifi
either
high
low
reactiv
analyz
singl
plasma
dilut
factor
mab
uninfect
patient
hivv
use
control
none
plasma
sampl
neutral
vsvg
pseudotyp
viru
data
shown
b
titrat
analys
neutral
activ
plasma
sampl
six
patient
exhibit
strong
reactiv
immunoreact
plasma
sampl
patient
analyz
seven
peptid
cluster
region
aa
eight
peptid
mper
aa
one
peptid
encompass
site
aa
neg
control
peptid
deriv
sarscov
protein
show
antibodi
reactiv
profil
similar
peptid
data
shown
includ
due
insuffici
amount
sampl
peptid
recogn
mab
indic
patient
sampl
react
significantli
peptid
recogn
arbitrarili
defin
valu
greater
twice
sum
averag
standard
deviat
sar
peptid
background
reactiv
indic
triangl
dot
respect
note
yaxi
seven
peptid
mper
differ
scale
